BioStem COO exercises options for 250,000 shares
The Chief Operating Officer's reported direct common-stock holdings were 1,789,809 shares after the exercise.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BioStem Technologies, Inc. Chief Operating Officer and director Vurst Andrew Smith-Van exercised options to acquire 250,000 common shares at an exercise price of $2 per share on October 7, 2026. His reported direct common-stock holdings after the transaction were 1,789,809 shares. The exercised options were fully vested and exercisable. Other reported direct options covered 114,314 and 23,246 shares at $10.05 per share, and 253,304 shares at $5.50 per share.
Insights
Analyzing...
Insider Trade Summary
250,000 shares exercised/converted
Exercise
9 txns
Insider
SMITH-VAN VURST ANDREW
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Options (Right to Buy) F4 | 250,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 250,000 | $2.00 | $500K |
| holding | Series A-1 Convertible Preferred Shares F1, F2, F3 | -- | -- | -- |
| holding | Options (Right to Buy) F5 | -- | -- | -- |
| holding | Options (Right to Buy) F6 | -- | -- | -- |
| holding | Options (Right to Buy) F7 | -- | -- | -- |
| holding | Restricted Stock Units F8, F9 | -- | -- | -- |
| holding | Restricted Stock Units F8, F10 | -- | -- | -- |
| holding | Restricted Stock Units F8, F11 | -- | -- | -- |
Holdings After Transaction:
Options (Right to Buy) — 2,390,864 contracts for 390,864 underlying shares (Direct);
Common Stock — 1,789,809 shares (Direct);
Series A-1 Convertible Preferred Shares — 100 contracts (Direct);
Restricted Stock Units — 297,020 contracts (Direct)
Footnotes (11)
- F1. The Series A-1 Convertible Preferred Shares are convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.
- F2. The Series A-1 Convertible Preferred Shares have no expiration date.
- F3. Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.
- F4. These options are fully vested and exercisable.
- F5. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F6. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F7. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F8. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F9. These restricted stock units will vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F10. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F11. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
Common shares acquired through option exercise: 250,000 shares
Option exercise price: $2 per share
Direct common shares held after transaction: 1,789,809 shares
+3 more
6 metrics
Common shares acquired through option exercise
250,000 shares
October 7, 2026
Option exercise price
$2 per share
Options exercised on October 7, 2026
Direct common shares held after transaction
1,789,809 shares
After the October 7, 2026 transaction
Other direct option shares
114,314 shares
Exercise price $10.05 per share; expiration March 17, 2035
Other direct option shares
23,246 shares
Exercise price $10.05 per share; expiration October 13, 2035
Other direct option shares
253,304 shares
Exercise price $5.50 per share; expiration February 11, 2036
Key Terms
fully vested and exercisable, Restricted Stock Units, contingent right, equal quarterly installments
4 terms
fully vested and exercisable financial
"These options are fully vested and exercisable."
Restricted Stock Units financial
"Restricted Stock Units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
equal quarterly installments financial
"will vest in equal quarterly installments over three years"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Vurst Andrew Smith-Van's BioStem holdings after the option exercise?
His reported direct common-stock holdings after the transaction were 1,789,809 shares.
What other BSEM options were reported?
Other direct option positions covered 114,314 shares at $10.05, expiring March 17, 2035; 23,246 shares at $10.05, expiring October 13, 2035; and 253,304 shares at $5.50, expiring February 11, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
